A detailed history of Black Rock Inc. transactions in Cel Sci Corp stock. As of the latest transaction made, Black Rock Inc. holds 774,704 shares of CVM stock, worth $821,186. This represents 0.0% of its overall portfolio holdings.

Number of Shares
774,704
Previous 763,443 1.48%
Holding current value
$821,186
Previous $1.46 Million 38.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.11 - $1.85 $12,499 - $20,832
11,261 Added 1.48%
774,704 $898,000
Q1 2024

May 10, 2024

BUY
$1.63 - $3.08 $14,079 - $26,605
8,638 Added 1.14%
763,443 $1.46 Million
Q4 2023

Feb 13, 2024

SELL
$1.07 - $3.07 $1,246 - $3,576
-1,165 Reduced 0.15%
754,805 $2.05 Million
Q3 2023

Nov 13, 2023

BUY
$1.17 - $2.86 $2,653 - $6,486
2,268 Added 0.3%
755,970 $944,000
Q2 2023

Aug 11, 2023

BUY
$2.11 - $2.83 $35,287 - $47,328
16,724 Added 2.27%
753,702 $1.82 Million
Q1 2023

May 12, 2023

SELL
$2.17 - $3.13 $126,001 - $181,743
-58,065 Reduced 7.3%
736,978 $1.71 Million
Q4 2022

Feb 13, 2023

SELL
$1.99 - $3.52 $612,824 - $1.08 Million
-307,952 Reduced 27.92%
795,043 $1.87 Million
Q3 2022

Nov 14, 2022

SELL
$3.09 - $5.23 $154,830 - $262,059
-50,107 Reduced 4.35%
1,102,995 $3.41 Million
Q2 2022

Aug 12, 2022

SELL
$2.58 - $4.99 $4.43 Million - $8.57 Million
-1,717,769 Reduced 59.83%
1,153,102 $5.19 Million
Q1 2022

May 12, 2022

SELL
$3.93 - $7.7 $280,358 - $549,302
-71,338 Reduced 2.42%
2,870,871 $11.3 Million
Q4 2021

Feb 10, 2022

BUY
$7.1 - $12.82 $539,032 - $973,294
75,920 Added 2.65%
2,942,209 $20.9 Million
Q3 2021

Nov 09, 2021

BUY
$7.64 - $12.49 $401,130 - $655,774
52,504 Added 1.87%
2,866,289 $31.5 Million
Q2 2021

Aug 11, 2021

BUY
$8.68 - $27.49 $24.4 Million - $77.4 Million
2,813,785 New
2,813,785 $24.4 Million

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $46M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.